Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas
Article first published online: 27 NOV 2012
© 2012 British Small Animal Veterinary Association
Journal of Small Animal Practice
Volume 54, Issue 1, pages 20–27, January 2013
How to Cite
Rivera, P., Åkerlund-Denneberg, N., Bergvall, K., Kessler, M., Rowe, A., Willmann, M., Persson, G., Kastengren Fröberg, G., Westberg, S. and von Euler, H. (2013), Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas. Journal of Small Animal Practice, 54: 20–27. doi: 10.1111/j.1748-5827.2012.01304.x
- Issue published online: 26 DEC 2012
- Article first published online: 27 NOV 2012
To determine the clinical efficacy and safety of a cremophor-free formulation of paclitaxel (Paccal Vet, Oasmia Pharmaceuticals) in dogs with mast cell tumours.
Paccal Vet was administered at a median dose of 145 (range, 135 to 150) mg/m2intravenously once every 21 days for three cycles to 29 dogs with macroscopic grade 2 or 3 mast cell tumour. Efficacy was assessed by tumour response (Response Evaluation Criteria in Solid Tumours version 1.0) and performance status score. Progression-free survival, quality of life and safety/adverse events were also evaluated. Clinical safety was assessed by clinicopathological analyses and recording of adverse events.
Complete or partial response was observed in 59% of dogs. Performance status score remained constant or improved for 20 dogs and decreased by one grade for 9 dogs. Median time to progression was 247 (range, 42 to 268) days. Expected, transient frequently subclinical adverse events (primarily grade 3/4 neutropenia and grade 1/2 leukopenia) were observed in the majority of dogs. Nine dogs were euthanased and one dog died due to disease progression.
Paccal Vet appears to be a clinically safe and effective treatment for canine mast cell tumours. Further controlled confirmatory investigation is warranted.